



Liver Diseases in Type I Diabetes Mellitus

Thesis

*Submitted for the Partial Fulfillment of Master
Degree in Pediatrics*

Presented by

Maha Mohammed El Saeed

M.B.B.Ch (2009)

Under supervision of

Prof. Dr. Manal Hamdy El Sayed

Professor of Pediatrics

Faculty of Medicine – Ain Shams University

Dr. Mohamed Tarif Salam

Ass. Professor of Clinical Pathology

Faculty of Medicine – Ain Shams University

Dr. Rasha Adel Fathy Thabet

Lecturer of Pediatrics

Faculty of Medicine – Ain Shams University

Faculty of Medicine

Ain Shams University

2018

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Manal Hamdy El Sayed**, Professor of Pediatrics Faculty of Medicine – Ain Shams University for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Mohamed Tariq Salam**, Assistant Professor of Clinical Pathology Faculty of Medicine – Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Rasha Adel Fathy Thabet**, Lecturer of Pediatrics Faculty of Medicine – Ain Shams University, for her great help, active participation and guidance.*

Maha El Saeed

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سُبْحَانَكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

List of Contents

Title	Page No.
List of Tables	5
List of Figures	7
List of Abbreviations	9
Introduction	i
Aim of the Work.....	13
Review of Literature	
▪ Type 1 Diabetes in Children	14
▪ Liver Affection in T1DM	31
Subjects and Methods	42
Results	47
Discussion	83
Summary	103
Conclusions & Recommendations.....	108
References	110
Arabic Summary	—

List of Tables

Table No.	Title	Page No.
Table (1):	Classification of T1DM	16
Table (2):	Criteria for the diagnosis of diabetes mellitus	21
Table (3):	Pharmacological profiles of insulin preparations	26
Table (4):	Guidelines regarding monitoring for complications in children with T1DM.....	29
Table (5):	Recommended targets for glycemic control and cardiovascular/renal risk factors.....	30
Table (6):	Baseline laboratory data among 107 type-1 DM patients.	47
Table (7):	Hepatic outcome data among 107 type-1 DM patients:	47
Table (8):	Comparison between the 2 groups as regards basic clinical data using Mann-Whitney's U and Chi square tests.	49
Table (9):	Comparison between the 2 groups as regards initial DM clinical data using Chi square test.....	52
Table (10):	Comparison between the 2 groups as regards DM complications Chi square test.....	54
Table (11):	Comparison between the 2 groups as regards baseline laboratory data using Mann-Whitney's U and Chi square tests.	55
Table (12):	Comparison between the 2 groups as regards baseline U/S data using Chi square test.....	58
Table (13):	Comparison between the 2 groups as regards baseline fibro-scan data using Mann-Whitney's U and Chi square tests:	61
Table (14):	Comparison between Elevated liver enzymes patients as regards serial laboratory assessments:	63

List of Tables Cont...

Table No.	Title	Page No.
Table (15):	Comparison between Elevated liver enzymes patients as regards serial U/S assessments:	66
Table (16):	Comparison between Elevated liver enzymes patients as regards serial Fibro-scan assessments:	67
Table (17):	Spearman's correlation analysis for baseline clinical/ laboratory/radiological Factors associated with AST elevations.	70
Table (18):	Spearman's correlation analysis for baseline clinical/ laboratory/radiological Factors associated with ALT elevations.	74
Table (19):	Multiple regression model for the Factors affecting AST elevation using Forward method.....	77
Table (20):	Multiple regression model for the Factors affecting ALT elevation using Forward method:.....	78
Table (21):	Logistic regression model for the Factors affecting Elevated liver enzymes occurrence using Forward method.	79
Table (22):	Roc-curve of some baseline laboratory/radiological Factors to predict patients with Elevated liver enzymes (9) from patients without (98).	80

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Pathogenesis of T1DM	20
Figure (2):	The metabolic pathways of glycogen synthesis in hepatocytes	33
Figure (3):	Liver biopsy, haematoxylin and eosin staining	37
Figure (4):	Liver biopsy, periodic acid-Schiff staining.....	37
Figure (5):	Elevated liver enzymes diagnosis among 107 type-1 DM patients.	48
Figure (6):	Comparison between the 2 groups as regards age of onset.	50
Figure (7):	Comparison between the 2 groups as regards family history of DM.....	51
Figure (8):	Comparison between the 2 groups as regards DKA.....	53
Figure (9):	Comparison between the 2 groups as regards baseline AST.	56
Figure (10):	Comparison between the 2 groups as regards baseline ALT.	56
Figure (11):	Comparison between the 2 groups as regards baseline HbA _{1c}	57
Figure (12):	Comparison between the 2 groups as regards hepatomegaly.....	59
Figure (13):	Comparison between the 2 groups as regards splenomegaly.....	59
Figure (14):	Comparison between the 2 groups as regards baseline overall U/S results.	60
Figure (15):	Comparison between the 2 groups as regards baseline Fibro-scan stage (F).....	62
Figure (16):	Comparison between the 2 groups as regards baseline overall fibro-scan results.....	62
Figure (17):	Comparison baseline and follow up AST measurements in Elevated liver enzymes patients.....	64

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (18):	Comparison baseline and follow up ALT measurements in Elevated liver enzymes patients.....	65
Figure (19):	Comparison baseline and follow up HbA _{1c} measurements in Elevated liver enzymes patients.....	65
Figure (20):	Comparison baseline and follow up fibro-scan F-stage measurements in Elevated liver enzymes patients.	68
Figure (21):	Correlation between AST and age of onset.	71
Figure (22):	Correlation between AST and DKA.	71
Figure (23):	Correlation between AST and baseline HbA _{1c}	72
Figure (24):	Correlation between AST and hepatomegaly.....	72
Figure (25):	Correlation between AST and splenomegaly.....	73
Figure (26):	Correlation between AST and fibro-scan F-stage.	73
Figure (27):	Correlation between ALT and HbA _{1c}	75
Figure (28):	Correlation between ALT and hepatomegaly.	75
Figure (29):	Correlation between ALT and splenomegaly.....	76
Figure (30):	Correlation between ALT and fibro-scan F-stage.	76
Figure (31):	ROC curve of AST, ALT and HbA _{1c}	82
Figure (32):	ROC curve of hepatomegaly, splenomegaly and F-stage.	82

List of Abbreviations

Abb.	Full term
ADA.....	<i>American Diabetes Association</i>
APEG.....	<i>Australasian Pediatric Endocrine Group</i>
BE.....	<i>Branching enzyme</i>
BMI.....	<i>Body mass index</i>
CD.....	<i>Celiac disease</i>
cm.....	<i>Centimeters</i>
DBE.....	<i>Debranching enzyme</i>
DCCT.....	<i>Diabetes Control and Complications Trial</i>
DKA.....	<i>Diabetic ketoacidosis</i>
DNs.....	<i>Diabetic neuropathies</i>
G6Pase.....	<i>Glucose-6-phos-phatase</i>
G6Pase.....	<i>Glucosio-6-phosphatase</i>
GCK.....	<i>Glucokinase</i>
GLUT.....	<i>Glucose transporter</i>
GP.....	<i>Glycogen phosphorylase</i>
GS.....	<i>Glycogen synthase</i>
GSK3.....	<i>Glycogen synthase kinase 3</i>
HAAF.....	<i>Hypoglycemia-associated autonomic failure</i>
HCC.....	<i>Hepatocellular carcinoma</i>
HG.....	<i>Hepatic glycogenosis</i>
ICR.....	<i>Insulin to carbohydrate ratio</i>
IQR.....	<i>Inter quartile range</i>
IR.....	<i>Insulin receptor</i>
IRS.....	<i>Insulin receptor substrate</i>
ISPAD.....	<i>International Society for Pediatric and Adolescent Diabetes</i>
Kg.....	<i>Kilograms</i>
KPa.....	<i>Kilopascal</i>
MODY.....	<i>Maturity-onset diabetes of the young</i>
MR.....	<i>Magnetic resonance</i>

List of Abbreviations Cont...

Abb.	Full term
<i>NAFLD</i>	<i>Non-alcoholic fatty liver disease</i>
<i>NASH</i>	<i>Non-alcoholic steatohepatitis</i>
<i>NGSP</i>	<i>National Glycohemoglobin Standardization Program</i>
<i>PAS</i>	<i>Periodic acid-Schiff-stained</i>
<i>PDK1/2</i>	<i>3-phosphoinositide-dependent protein kinase 1 and 2</i>
<i>PEPCK</i>	<i>Phosphoenolpyruvate carboxykinase</i>
<i>PGM</i>	<i>Phosphoglucomutase</i>
<i>PI3K</i>	<i>Phosphatidylinositol-3-kinase</i>
<i>PIP2</i>	<i>Phosphatidylinositol (3,4)-bisphosphate</i>
<i>PIP3</i>	<i>Phosphatidylinositol (3,4,5)-trisphosphate</i>
<i>PKB/Akt</i>	<i>Protein kinase B</i>
<i>PPi</i>	<i>Pyrophosphate</i>
<i>PTMs</i>	<i>Post-translational modifications</i>
<i>PTPN2</i>	<i>Protein tyrosine phosphatase non-receptor type 22</i>
<i>SPSS</i>	<i>Statistical Package for Social Science</i>
<i>T1D</i>	<i>Type 1 diabetes</i>
<i>T1DM</i>	<i>Type 1 diabetes mellitus</i>
<i>UDP</i>	<i>Uridinediphosphate</i>
<i>UDPGPP</i>	<i>UDP-glucosepyrophosphorylase</i>
<i>UTP</i>	<i>Uridine triphosphate</i>

INTRODUCTION

Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Metabolic abnormalities in carbohydrates, lipids, and proteins result from the importance of insulin as an anabolic hormone (*Kharroubi and Darwish, 2015*).

A complex interaction of genetic and environmental factors can trigger the immune-mediated mechanism responsible for type 1 diabetes mellitus (T1DM) establishment. Environmental factors may initiate and possibly sustain, accelerate, or retard damage to β -cells (*Bergamin and Dib, 2015*).

Hepatic glycogenosis (HG) is characterized by excessive glycogen accumulation in hepatocytes and represents a hepatic complication of diabetes that particularly occurs in patients with longstanding poorly controlled type 1 diabetes (T1DM). HG has been reported to be a very rare disease, although it is believed to be extremely underdiagnosed because it is not possible to distinguish it from non-alcoholic fatty liver disease (NAFLD) unless a liver biopsy is performed (*Julián et al., 2015*).

The imaging study (ultrasonography and/or radiological examinations) gives information about the liver alterations (hepatomegaly), but the diagnosis needs to be confirmed by the liver biopsy (*Giordano et al., 2014*).

Glycogenic hepatopathy (GH) is an under-recognised complication of type 1 diabetes mellitus (T1DM) not controlled to target resulting in hepatomegaly and elevated liver transaminases (*Irani et al., 2015*).

Fibroscan is anon invasive and not painful technique used in measurement of liver stiffness. Fibroscan may included in management of HCV (*Chou and Wasson, 2013*).

AIM OF THE WORK

The aim of this study is to determine liver diseases in children and adolescents with type1 diabetes mellitus by detection of elevated liver transminases and confirmed by fibroscan and ultrasound.

Chapter 1**TYPE 1 DIABETES IN CHILDREN**

Diabetes mellitus is a common metabolic disorder that is caused by a deficit in the production of (type 1) or response to (type 2) insulin. Diabetes mellitus is characterized by a state of chronic hyperglycemia and such symptoms as weight loss, thirst, polyuria, and blurred vision (*Stolf et al., 2017*).

In most instances, T1DM represent as an immune, if not autoimmune-mediated disorder where patients usually show features of an immunological basis to disease pathogenesis (e.g. autoantibodies or genetic associations with genes governing immune responses) (*Eisenbarth, 2007*).

Nevertheless, not all patients with T1DM have these characteristics. This variation leads to emergence of the proposed classifications of type 1A (autoimmune) diabetes, for the 70-90% of patients with type 1 disease that have immunological, self-reactive autoantibodies, and type 1B (idiopathic) diabetes, which describes other patients with no evidence of specific pathogenesis (*Gianani et al., 2010*).

A subset of individuals within this latter group have monogenic forms of diabetes, such as maturity onset diabetes of the young (MODY) (*Hattersley et al., 2009*). Despite knowledge gains that could allow for adopting this new set of

terminologies for subgrouping cases of type 1 diabetes, the terms type 1A and type 1B diabetes are not commonly used (*Dabelea et al., 2007*).

Diabetes can be classified into the following general categories:

1. Type 1 diabetes (due to autoimmune b-cell destruction, usually leading to absolute insulin deficiency).
2. Type 2 diabetes (due to a progressive loss of b-cell insulin secretion frequently on the background of insulin resistance).
3. Gestational diabetes mellitus (GDM) (diabetes diagnosed in the second or third trimester of pregnancy that was not clearly overt diabetes prior to gestation).
4. Specific types of diabetes due to other causes, e.g., monogenic diabetes syndromes (such as neonatal diabetes and maturity-onset diabetes of the young [MODY]), diseases of the exocrine pancreas (such as cystic fibrosis), and drug- or chemical-induced diabetes (such as with glucocorticoid use, in the treatment of HIV/AIDS, or after organ transplantation).

(American Diabetes Association, 2017)